Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

NCT07340463 is registered in ClinicalTrials.gov with Nanjing University School of Medicine as lead sponsor.

NCT NCT07340463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07340463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
Lead sponsor
Nanjing University School of Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
December 8, 2025
Completion date
June 30, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis (ln), systemic lupus erythematosus (sle)